ASHP Advantage's Engaging the Experts

✓

Tuntutan

In Part 2 of this three-part interview on revised USP Chapter <797>, William Zellmer talks with Patricia Kienle, Ashley Duty, and Eric Kastango about changes that may be needed to get your facility ready.

In Part 1 of this three-part interview on revised USP Chapter <797>, William Zellmer talks with Patricia Kienle, Ashley Duty, and Eric Kastango about key changes to note.

William Zellmer talks with John Petrich and Michael Storey about gene therapies and considerations for integrating them into pharmacy practice.

Angela Cassano talks with Ryan Forrey about insourcing compounded sterile products and how he addressed the challenges faced at Emory University Hospital Midtown.

Part 2: Future Treatment Options and Roles for Pharmacists in Individualizing Insulin Therapy In Part 2 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding future treatment options for type 2 diab ...

Part 1: Barriers to Optimizing the Use of Insulin in Managing Type 2 Diabetes In Part 1 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding the barriers to optimizing the use of insulin in managing p ...

In Part 1 of this two-part “Engaging the Experts” interview, William Zellmer talks with Edward Li and James Stevenson regarding the status of biosimilars in the European Union and United States. Faculty: Edward C. Li, Pharm.D., M.P.H., BCOP, Activity Chair Associate Professor Department of P ...

In Part 2 of this two-part “Engaging the Experts” interview, William Zellmer talks with Edward Li and James Stevenson regarding biosimilars, focusing on interchangeability and the integration of biosimilars into the medication-use system. Faculty: Edward C. Li, Pharm.D., M.P.H., BCOP, Activit ...

William Zellmer talks with Susan Cornell and Curtis Triplitt about SGLT2 inhibitors, one of the newest classes of oral diabetes medications. With an increasing number of both oral and injectable medications, the faculty explore how SGLT2 inhibitors fit into clinical practice. Faculty: Susan C ...